stockportfolio.pro
Aura Biosciences, Inc. (AURA)
Healthcare · Biotechnology · NasdaqGM
Aura Biosciences, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-22.21M | $-35.25M | $-58.76M | $-76.41M | $-86.92M | $-106.19M |
| Net margin | — | — | — | — | — | — |
Source: Aura Biosciences, Inc. SEC filings (10-K).
Explore 6 years of Aura Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AURA in your portfolio →
Aura Biosciences, Inc. financial history by metric
About Aura Biosciences, Inc.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Aura Biosciences, Inc. — frequently asked questions
What is Aura Biosciences, Inc.'s revenue?
Aura Biosciences, Inc. (AURA) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Aura Biosciences, Inc. profitable?
No — AURA reported a net loss of $-106.19M in fiscal 2025.
What is AURA's P/E ratio?
Aura Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Aura Biosciences, Inc. have?
As of fiscal year 2025, AURA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Aura Biosciences, Inc.'s market cap?
Aura Biosciences, Inc. (AURA) has a market capitalization of about $652.37M, based on the latest data in our nightly-refreshed cache.
When does Aura Biosciences, Inc.'s fiscal year end?
AURA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Aura Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.